NSAID use and risk of leukaemia: a population-based case-control study
Purpose The use of non‐steroidal anti‐inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting similar associations in leukaemia have been small and underpowered. We have conducted a large population‐based case‐control study to determ...
Saved in:
Published in | Pharmacoepidemiology and drug safety Vol. 18; no. 9; pp. 833 - 836 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Chichester, UK
John Wiley & Sons, Ltd
01.09.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Purpose
The use of non‐steroidal anti‐inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting similar associations in leukaemia have been small and underpowered. We have conducted a large population‐based case‐control study to determine whether the use of NSAIDs is associated with a reduced risk of acute and chronic leukaemias, and whether their use has any impact on survival in these patients.
Methods
We identified all the incident cases of leukaemia in ‘The Health Improvement Network’ (THIN) general practice dataset, along with at least four matched controls per case. We used conditional logistic regression to determine odds ratios for NSAID prescription rates and the risk of developing several leukaemia sub‐types. We then used Cox regression to determine the association between NSAID prescription rate and risk of death in leukaemia. Hazard ratios were adjusted for gender, age at diagnosis, smoking status and Townsend Score.
Results
The risk of leukaemia overall appears to increase marginally with increased use of NSAIDs prior to diagnosis. This is not seen when individual leukaemia sub‐types are examined, however, except perhaps in CLL where patients who had received 2–5 prescriptions/year are 34% more likely to be diagnosed with CLL than those who had not had any NSAID prescriptions (O.R. 1.34, p = 0.03, 95% C.I. 1.02–1.74). There was no statistically significant association between exposure to NSAIDs prior to leukaemia diagnosis and survival.
Conclusion
The use of NSAIDs does not reduce the risk of developing leukaemia, nor do they improve survival. Copyright © 2009 John Wiley & Sons, Ltd. |
---|---|
AbstractList | Purpose The use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting similar associations in leukaemia have been small and underpowered. We have conducted a large population-based case-control study to determine whether the use of NSAIDs is associated with a reduced risk of acute and chronic leukaemias, and whether their use has any impact on survival in these patients. Methods We identified all the incident cases of leukaemia in 'The Health Improvement Network' (THIN) general practice dataset, along with at least four matched controls per case. We used conditional logistic regression to determine odds ratios for NSAID prescription rates and the risk of developing several leukaemia sub-types. We then used Cox regression to determine the association between NSAID prescription rate and risk of death in leukaemia. Hazard ratios were adjusted for gender, age at diagnosis, smoking status and Townsend Score. Results The risk of leukaemia overall appears to increase marginally with increased use of NSAIDs prior to diagnosis. This is not seen when individual leukaemia sub-types are examined, however, except perhaps in CLL where patients who had received 2-5prescriptions/year are 34% more likely to be diagnosed with CLL than those who had not had any NSAID prescriptions (O.R. 1.34, p=0.03, 95% C.I. 1.02-1.74). There was no statistically significant association between exposure to NSAIDs prior to leukaemia diagnosis and survival. Conclusion The use of NSAIDs does not reduce the risk of developing leukaemia, nor do they improve survival. The use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting similar associations in leukaemia have been small and underpowered. We have conducted a large population-based case-control study to determine whether the use of NSAIDs is associated with a reduced risk of acute and chronic leukaemias, and whether their use has any impact on survival in these patients. We identified all the incident cases of leukaemia in 'The Health Improvement Network' (THIN) general practice dataset, along with at least four matched controls per case. We used conditional logistic regression to determine odds ratios for NSAID prescription rates and the risk of developing several leukaemia sub-types. We then used Cox regression to determine the association between NSAID prescription rate and risk of death in leukaemia. Hazard ratios were adjusted for gender, age at diagnosis, smoking status and Townsend Score. The risk of leukaemia overall appears to increase marginally with increased use of NSAIDs prior to diagnosis. This is not seen when individual leukaemia sub-types are examined, however, except perhaps in CLL where patients who had received 2-5 prescriptions/year are 34% more likely to be diagnosed with CLL than those who had not had any NSAID prescriptions (O.R. 1.34, p = 0.03, 95% C.I. 1.02-1.74). There was no statistically significant association between exposure to NSAIDs prior to leukaemia diagnosis and survival. The use of NSAIDs does not reduce the risk of developing leukaemia, nor do they improve survival. Purpose The use of non‐steroidal anti‐inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting similar associations in leukaemia have been small and underpowered. We have conducted a large population‐based case‐control study to determine whether the use of NSAIDs is associated with a reduced risk of acute and chronic leukaemias, and whether their use has any impact on survival in these patients. Methods We identified all the incident cases of leukaemia in ‘The Health Improvement Network’ (THIN) general practice dataset, along with at least four matched controls per case. We used conditional logistic regression to determine odds ratios for NSAID prescription rates and the risk of developing several leukaemia sub‐types. We then used Cox regression to determine the association between NSAID prescription rate and risk of death in leukaemia. Hazard ratios were adjusted for gender, age at diagnosis, smoking status and Townsend Score. Results The risk of leukaemia overall appears to increase marginally with increased use of NSAIDs prior to diagnosis. This is not seen when individual leukaemia sub‐types are examined, however, except perhaps in CLL where patients who had received 2–5 prescriptions/year are 34% more likely to be diagnosed with CLL than those who had not had any NSAID prescriptions (O.R. 1.34, p = 0.03, 95% C.I. 1.02–1.74). There was no statistically significant association between exposure to NSAIDs prior to leukaemia diagnosis and survival. Conclusion The use of NSAIDs does not reduce the risk of developing leukaemia, nor do they improve survival. Copyright © 2009 John Wiley & Sons, Ltd. PURPOSEThe use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting similar associations in leukaemia have been small and underpowered. We have conducted a large population-based case-control study to determine whether the use of NSAIDs is associated with a reduced risk of acute and chronic leukaemias, and whether their use has any impact on survival in these patients.METHODSWe identified all the incident cases of leukaemia in 'The Health Improvement Network' (THIN) general practice dataset, along with at least four matched controls per case. We used conditional logistic regression to determine odds ratios for NSAID prescription rates and the risk of developing several leukaemia sub-types. We then used Cox regression to determine the association between NSAID prescription rate and risk of death in leukaemia. Hazard ratios were adjusted for gender, age at diagnosis, smoking status and Townsend Score.RESULTSThe risk of leukaemia overall appears to increase marginally with increased use of NSAIDs prior to diagnosis. This is not seen when individual leukaemia sub-types are examined, however, except perhaps in CLL where patients who had received 2-5 prescriptions/year are 34% more likely to be diagnosed with CLL than those who had not had any NSAID prescriptions (O.R. 1.34, p = 0.03, 95% C.I. 1.02-1.74). There was no statistically significant association between exposure to NSAIDs prior to leukaemia diagnosis and survival.CONCLUSIONThe use of NSAIDs does not reduce the risk of developing leukaemia, nor do they improve survival. Abstract Purpose The use of non‐steroidal anti‐inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting similar associations in leukaemia have been small and underpowered. We have conducted a large population‐based case‐control study to determine whether the use of NSAIDs is associated with a reduced risk of acute and chronic leukaemias, and whether their use has any impact on survival in these patients. Methods We identified all the incident cases of leukaemia in ‘The Health Improvement Network’ (THIN) general practice dataset, along with at least four matched controls per case. We used conditional logistic regression to determine odds ratios for NSAID prescription rates and the risk of developing several leukaemia sub‐types. We then used Cox regression to determine the association between NSAID prescription rate and risk of death in leukaemia. Hazard ratios were adjusted for gender, age at diagnosis, smoking status and Townsend Score. Results The risk of leukaemia overall appears to increase marginally with increased use of NSAIDs prior to diagnosis. This is not seen when individual leukaemia sub‐types are examined, however, except perhaps in CLL where patients who had received 2–5 prescriptions/year are 34% more likely to be diagnosed with CLL than those who had not had any NSAID prescriptions (O.R. 1.34, p = 0.03, 95% C.I. 1.02–1.74). There was no statistically significant association between exposure to NSAIDs prior to leukaemia diagnosis and survival. Conclusion The use of NSAIDs does not reduce the risk of developing leukaemia, nor do they improve survival. Copyright © 2009 John Wiley & Sons, Ltd. |
Author | Bhayat, F. Das-Gupta, E. Smith, C. Hubbard, R. |
Author_xml | – sequence: 1 givenname: F. surname: Bhayat fullname: Bhayat, F. email: mcxfb1@exmail.nottingham.ac.uk organization: Division of Epidemiology and Public Health, University of Nottingham,UK – sequence: 2 givenname: E. surname: Das-Gupta fullname: Das-Gupta, E. organization: Division of Academic Haematology, University of Nottingham, UK – sequence: 3 givenname: C. surname: Smith fullname: Smith, C. organization: Division of Epidemiology and Public Health, University of Nottingham,UK – sequence: 4 givenname: R. surname: Hubbard fullname: Hubbard, R. organization: Division of Epidemiology and Public Health, University of Nottingham,UK |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19551758$$D View this record in MEDLINE/PubMed |
BookMark | eNp90E9LwzAYBvAgitMp-AkkJ_HSmTTNkngT558xnQMVwUtI2rdQ1zW1adF9ezMsetJLEsiPh_d99tF25SpA6IiSESUkPqszP6JCqi20R4lSEeVcbG_enEWSj9UA7Xv_Rkj4U8kuGlDFORVc7qHr-ePFdII7D9hUGW4Kv8QuxyV0SwOrwpxjg2tXd6VpC1dF1njIcBrOKHVV27gS-7bL1gdoJzelh8P-HqLn66uny9vo7uFmenlxF6VMkTCXUCJWliojrbQkyQVXFgjkllqZcyGFMFLRsZJgWcYhiXkiCJHWpDZRkLAhOvnOrRv33oFv9arwKZSlqcB1Xo_FmCSCsQBP_4WhJpbweGN_aNo47xvIdd0UK9OsA9KbenWoV2_qDfS4T-3sCrJf2PcZQPQNPooS1n8G6cXksQ_sfeFb-PzxplmGVZjg-mV-o18ni1k8W9xrzr4AZmqS0Q |
CitedBy_id | crossref_primary_10_1002_pds_1846 crossref_primary_10_1016_j_bbrc_2012_02_092 crossref_primary_10_1016_j_canep_2014_08_003 crossref_primary_10_1158_1055_9965_EPI_11_0411 crossref_primary_10_1002_pds_2191 |
Cites_doi | 10.1592/phco.23.5.686.32205 10.1038/sj.bjc.6604151 10.7326/0003-4819-121-4-199408150-00001 10.1378/chest.127.3.748 10.1136/bmj.302.6779.766 10.1136/bmj.320.7250.1642 10.1186/1471-2407-2-31 10.1016/S0140-6736(07)60747-8 10.1056/NEJMoa021735 10.1002/ijc.20788 |
ContentType | Journal Article |
Copyright | Copyright © 2009 John Wiley & Sons, Ltd. |
Copyright_xml | – notice: Copyright © 2009 John Wiley & Sons, Ltd. |
DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T2 7U1 7U2 C1K 7X8 |
DOI | 10.1002/pds.1789 |
DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Health and Safety Science Abstracts (Full archive) Risk Abstracts Safety Science and Risk Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Risk Abstracts Health & Safety Science Abstracts Safety Science and Risk Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Risk Abstracts MEDLINE MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1099-1557 |
EndPage | 836 |
ExternalDocumentID | 10_1002_pds_1789 19551758 PDS1789 ark_67375_WNG_ZDPK2KPM_5 |
Genre | article Journal Article |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 123 1L6 1OB 1OC 1ZS 31~ 33P 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA GWYGA H.X HF~ HGLYW HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES M6Q MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWI RX1 RYL SAMSI SUPJJ SV3 TEORI UB1 V8K W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WWP WXI WXSBR XG1 XV2 YCJ ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T2 7U1 7U2 C1K 7X8 |
ID | FETCH-LOGICAL-c3909-179729b19a8b8b04f759be0efb1b8f57877a891698eb3d5e42547008bacb49e43 |
IEDL.DBID | DR2 |
ISSN | 1053-8569 1099-1557 |
IngestDate | Fri Aug 16 05:19:45 EDT 2024 Fri Aug 16 11:55:11 EDT 2024 Fri Aug 23 01:16:53 EDT 2024 Sat Sep 28 07:55:52 EDT 2024 Sat Aug 24 00:53:21 EDT 2024 Wed Oct 30 09:53:27 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3909-179729b19a8b8b04f759be0efb1b8f57877a891698eb3d5e42547008bacb49e43 |
Notes | No conflict of interest is found in this paper istex:98AD24F0FDE6002EDD8EE05D1296E905BEBFEDB4 ArticleID:PDS1789 ark:/67375/WNG-ZDPK2KPM-5 Epidemiology. Public Health. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
PMID | 19551758 |
PQID | 1093452473 |
PQPubID | 23462 |
PageCount | 4 |
ParticipantIDs | proquest_miscellaneous_67604733 proquest_miscellaneous_1093452473 crossref_primary_10_1002_pds_1789 pubmed_primary_19551758 wiley_primary_10_1002_pds_1789_PDS1789 istex_primary_ark_67375_WNG_ZDPK2KPM_5 |
PublicationCentury | 2000 |
PublicationDate | September 2009 |
PublicationDateYYYYMMDD | 2009-09-01 |
PublicationDate_xml | – month: 09 year: 2009 text: September 2009 |
PublicationDecade | 2000 |
PublicationPlace | Chichester, UK |
PublicationPlace_xml | – name: Chichester, UK – name: England |
PublicationTitle | Pharmacoepidemiology and drug safety |
PublicationTitleAlternate | Pharmacoepidem. Drug Safe |
PublicationYear | 2009 |
Publisher | John Wiley & Sons, Ltd |
Publisher_xml | – name: John Wiley & Sons, Ltd |
References | Olsen JH, Friis S, Poulsen AH, Fryzek J, Harving H, Tjonneland A, et al. Use of NSAIDs, smoking and lung cancer risk. Br J Canc 2008; 98(1): 232-237. Moysich KB, Menezes RJ, Ronsani A, Swede H, Reid ME, Cummings KM, et al. Regular aspirin use and lung cancer risk. BMC Cancer 2002; 2: 31. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J 1991; 302(6779): 766-768. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Canc Res 1993; 53(6): 1322-1327. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369(9573): 1603-1613. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23(5): 686-689. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. New Engl J Med 2003; 348(10): 891-899. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. Br Med J 2000; 320(7250): 1642-1646. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121(4): 241-246. Khuder SA, Herial NA, Mutgi AB, Federman DJ. Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis. Chest 2005; 127(3): 748-754. Kasum CM, Blair CK, Folsom AR, Ross JA. Non-steroidal anti-inflammatory drug use and risk of adult leukemia. Canc Epidemiol Biomarkers Prev 2003; 12(6): 534-753. Pogoda JM, Katz J, McKean-Cowdin R, Nichols PW, Ross RK, Preston-Martin S. Prescription drug use and risk of acute myeloid leukemia by French-American-British subtype: results from a Los Angeles County case-control study. Int J Canc 2005; 114(4): 634-638. 1994; 121 2007; 369 2003; 348 2005; 114 1993; 53 2005; 127 2002; 2 2007 2008; 98 2000; 320 1991; 302 2003; 12 1999 2003; 23 Thun MJ (e_1_2_1_4_2) 1993; 53 e_1_2_1_6_2 e_1_2_1_7_2 e_1_2_1_5_2 e_1_2_1_2_2 e_1_2_1_3_2 e_1_2_1_12_2 e_1_2_1_10_2 Kasum CM (e_1_2_1_11_2) 2003; 12 e_1_2_1_15_2 e_1_2_1_13_2 e_1_2_1_14_2 e_1_2_1_8_2 e_1_2_1_9_2 |
References_xml | – volume: 348 start-page: 891 issue: 10 year: 2003 end-page: 899 article-title: A randomized trial of aspirin to prevent colorectal adenomas publication-title: New Engl J Med – volume: 302 start-page: 766 issue: 6779 year: 1991 end-page: 768 article-title: Validation of information recorded on general practitioner based computerised data resource in the United Kingdom publication-title: Br Med J – volume: 127 start-page: 748 issue: 3 year: 2005 end-page: 754 article-title: Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis publication-title: Chest – volume: 114 start-page: 634 issue: 4 year: 2005 end-page: 638 article-title: Prescription drug use and risk of acute myeloid leukemia by French‐American‐British subtype: results from a Los Angeles County case‐control study publication-title: Int J Canc – volume: 23 start-page: 686 issue: 5 year: 2003 end-page: 689 article-title: Validity of the general practice research database publication-title: Pharmacotherapy – volume: 369 start-page: 1603 issue: 9573 year: 2007 end-page: 1613 article-title: Effect of aspirin on long‐term risk of colorectal cancer: consistent evidence from randomised and observational studies publication-title: Lancet – year: 2007 – volume: 121 start-page: 241 issue: 4 year: 1994 end-page: 246 article-title: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals publication-title: Ann Intern Med – volume: 320 start-page: 1642 issue: 7250 year: 2000 end-page: 1646 article-title: Effect of anti‐inflammatory drugs on overall risk of common cancer: case‐control study in general practice research database publication-title: Br Med J – volume: 98 start-page: 232 issue: 1 year: 2008 end-page: 237 article-title: Use of NSAIDs, smoking and lung cancer risk publication-title: Br J Canc – volume: 12 start-page: 534 issue: 6 year: 2003 end-page: 753 article-title: Non‐steroidal anti‐inflammatory drug use and risk of adult leukemia publication-title: Canc Epidemiol Biomarkers Prev – volume: 2 start-page: 31 year: 2002 article-title: Regular aspirin use and lung cancer risk publication-title: BMC Cancer – volume: 53 start-page: 1322 issue: 6 year: 1993 end-page: 1327 article-title: Aspirin use and risk of fatal cancer publication-title: Canc Res – year: 1999 – ident: e_1_2_1_15_2 doi: 10.1592/phco.23.5.686.32205 – ident: e_1_2_1_5_2 doi: 10.1038/sj.bjc.6604151 – ident: e_1_2_1_3_2 doi: 10.7326/0003-4819-121-4-199408150-00001 – volume: 53 start-page: 1322 issue: 6 year: 1993 ident: e_1_2_1_4_2 article-title: Aspirin use and risk of fatal cancer publication-title: Canc Res contributor: fullname: Thun MJ – ident: e_1_2_1_6_2 doi: 10.1378/chest.127.3.748 – ident: e_1_2_1_13_2 – ident: e_1_2_1_14_2 doi: 10.1136/bmj.302.6779.766 – ident: e_1_2_1_2_2 doi: 10.1136/bmj.320.7250.1642 – ident: e_1_2_1_7_2 doi: 10.1186/1471-2407-2-31 – ident: e_1_2_1_8_2 doi: 10.1016/S0140-6736(07)60747-8 – ident: e_1_2_1_9_2 doi: 10.1056/NEJMoa021735 – ident: e_1_2_1_12_2 – ident: e_1_2_1_10_2 doi: 10.1002/ijc.20788 – volume: 12 start-page: 534 issue: 6 year: 2003 ident: e_1_2_1_11_2 article-title: Non‐steroidal anti‐inflammatory drug use and risk of adult leukemia publication-title: Canc Epidemiol Biomarkers Prev contributor: fullname: Kasum CM |
SSID | ssj0009994 |
Score | 1.9382392 |
Snippet | Purpose
The use of non‐steroidal anti‐inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies... The use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting... Abstract Purpose The use of non‐steroidal anti‐inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies... Purpose The use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies... PURPOSEThe use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting... |
SourceID | proquest crossref pubmed wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 833 |
SubjectTerms | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Antiinflammatory agents Cancer Case-Control Studies chemo-prevention epidemiology Gender Humans leukaemia Leukemia Leukemia - epidemiology Logistic Models Lung cancer Mortality non-steroidal anti-inflammatory drugs Risk Factors Risk reduction Smoking Survival |
Title | NSAID use and risk of leukaemia: a population-based case-control study |
URI | https://api.istex.fr/ark:/67375/WNG-ZDPK2KPM-5/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpds.1789 https://www.ncbi.nlm.nih.gov/pubmed/19551758 https://search.proquest.com/docview/1093452473 https://search.proquest.com/docview/67604733 |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELYqeukF-uCxhbZGQnsiSzZxYrs31C3lIVYRD4HgYNmxI6FtsyuykUpP_Qn9jf0lnUk2G1GBhLgkijSJHM94_Nkz85mQLWmNH1iLIX_nPKZF7GnDOe42cR6Dd-RVUdjxMN4_Z4eX0eUsqxJrYWp-iPmGG46Myl_jANem2GlJQye26PW5wNq9fsgxm2tw0jJHAe6pAspgY56IYtnwzvrBTvPivZnoJXbqz4dg5n3UWk07e0vkumlwnW0y6pVT00t__cfl-Lw_ek0WZ2iU7tbm84a8cPlb0k1qOuu7bXrWVmcV27RLk5bo-u4dORye7h4MaFk4qnNLMUudjjP63ZUj7X7c6M9U08n8gLC_v__glGlpCld4mCXJ04rgdpmc7309-7Lvzc5m8NJQ4gkKXAIsN32phRHGZxmPpHG-y0zfiAzdANcCoKcUsFq3kQPXwDjgDaNTw6Rj4QpZyMe5WyPUMuvSjMGbKWM2SLXQSJoDUMdEBhYAHbLZ6ElNagoOVZMtBwq6TGGXdUi3UuBcQN-OMGWNR-pi-E1dDZKj4Cg5VhF8rNGwgoGE0RGdu3FZYCg-ZFHAeNghnx6RiXnsgwBIrNbG0TZIAvSEtRc0pFLxoy1VyeAU7--fKrhOXtURLMxr2yAL09vSfQAgNDUfK5P_B0d-BWE |
link.rule.ids | 315,783,787,1378,27936,27937,46306,46730 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fa9swEBdd-7C9tPvbpvtTDUae6tSxZUvansqyLm2aYNaUlTEQkiVDyeaEJoZ1T_sI-4z7JLuz45iOFcZebAxnc5Z0p590p98R8kpa4wfWYsjfOY9pEXvacI67TZzH4B15eShsOIr75-zkIrpYI2_qszAVP8Rqww0to_TXaOC4IX3QsIbO7LzT5ULeIRtg7SHWbeh9aLijAPmUIWUYZZ6IYlkzz_rBQf3mjbloA5v129-A5k3cWk48R1vkc61ylW8y6RQL00m__8Hm-J__dJ9sLgEpPaxG0AOy5vKHpJ1UjNbX-3TcHNCa79M2TRqu6-tH5GR0dnjco8XcUZ1bionqdJrRL66YaPf1Ur-mms5WNcJ-_fiJs6alKVzhYZknT0uO28fk_Ojd-G3fW5Zn8NJQYhEFLgGZm67Uwgjjs4xH0jjfZaZrRIaegGsB6FMKWLDbyIF3YBwgh9GpYdKx8AlZz6e52yHUMuvSjMGbKWM2SLXQyJsDaMdEBtYALfKy7ig1q1g4VMW3HChoMoVN1iLtsgdXAvpqgllrPFIfR-_Vp14yCAbJUEXwsbqLFdgSBkh07qbFHKPxIYsCxsMW2btFJuaxDwIgsV2NjkYhCegTll-gSNnHt2qqkt4Z3nf_VXCP3O2Ph6fq9Hg0eEruVQEtTHN7RtYXV4V7DrhoYV6U4_83fq8JeQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED_BJiFe-P4oXzMS6tPSpakT27xNlLKtrIrYJqbxYNmxI6FCWq2NxHjiT-Bv5C_hLmkaDTEJ8ZIo0iW6-M7nn33nnwFeKWfDyDlK-XsfcCOTwFghaLVJiASjo6g2hR1Okr0TfnAan66qKmkvTM0PsV5wo55RxWvq4HOX77SkoXO36PWFVNdhkycIfAkQfWipoxD4VBlldLJAxolqiGfDaKd589JQtEmt-u1vOPMybK3GndFt-NRoXJebTHvl0vay73-QOf7fL92BWys4ynZr_7kL13xxD7ppzWd9sc2O2-1Zi23WZWnLdH1xHw4mR7v7Q1YuPDOFY1SmzmY5--LLqfFfP5vXzLD5-oSwXz9-0pjpWIZXfFhVybOK4fYBnIzeHr_ZC1aHMwTZQNERCkIhLrd9ZaSVNuS5iJX1oc9t38qc4oAwErGnkjhdd7HH2MAFAg5rMsuV54OHsFHMCv8YmOPOZznHNzPOXZQZaYg1B7GOjS3OADrwsrGTntccHLpmW440NpmmJutAtzLgWsCcT6lmTcT64-SdPhum42icHuoYP9ZYWGNPovSIKfysXFAufsDjiItBB7aukElEEqIASjyqnaNVSCH2xMkXKlKZ-EpNdTo8ovuTfxXcghvpcKTf70_GT-Fmnc2iGrdnsLE8L_1zBEVL-6Ly_t9mDwgo |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=NSAID+use+and+risk+of+leukaemia%3A+a+population-based+case-control+study&rft.jtitle=Pharmacoepidemiology+and+drug+safety&rft.au=Bhayat%2C+F.&rft.au=Das-Gupta%2C+E.&rft.au=Smith%2C+C.&rft.au=Hubbard%2C+R.&rft.date=2009-09-01&rft.pub=John+Wiley+%26+Sons%2C+Ltd&rft.issn=1053-8569&rft.eissn=1099-1557&rft.volume=18&rft.issue=9&rft.spage=833&rft.epage=836&rft_id=info:doi/10.1002%2Fpds.1789&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_ZDPK2KPM_5 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1053-8569&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1053-8569&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1053-8569&client=summon |